Clinical trials: Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
The purpose of this study is to to evaluate the effect of ASP0367 on improvement of aerobic capacity relative to placebo, as well as evaluate the safety and tolerability of ASP0367 relative to placebo.
- Trial name
- NCT04855201
- Testing
- Bocidelpar
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Astellas Pharma Global Development, Inc.